Approaches to Switching Therapies for Patients With MF

When switching JAK inhibitors for myelofibrosis, Aaron Gerds, MD, MS, advises stopping ruxolitinib and starting the new JAK inhibitor the next day due to its short half-life, though tapering ruxolitinib over 1 week is recommended for patients on higher doses to avoid rebound symptoms; pacritinib and fedratinib have longer half-lives so a 1-week washout can be considered.

EP: 1.Available Treatment Options for Patients With Higher-Risk Myelofibrosis

EP: 2.Current Unmet Needs in the Treatment of Myelofibrosis

EP: 3.Emerging Treatments for Patients With Myelofibrosis

EP: 4.Case Presentation: A 73-Year-Old Man with Myelofibrosis (MF)

EP: 5.Risk Stratification of Patients With MF

EP: 6.Current Treatment Landscape for Patients With MF

EP: 7.Momelotinib in Patients With MF

EP: 8.Monitoring Patients on Treatment for MF

Now Viewing

EP: 9.Approaches to Switching Therapies for Patients With MF

EP: 10.Factors for Consideration When Selecting a JAK Inhibitor for Patients With MF

EP: 11.Safety of Available JAK Inhibitors for Treatment of MF

EP: 12.Future of Myelofibrosis Treatments

Recent Videos